Amerikanische Gesellschaft für Hirudotherapie

Emergency Reversal of Antithrombotics in Intracerebral Hemorrhage: An Update

Review published in Current neurology and neuroscience reports (2025)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienSpeichel-PharmakologieLi M et al. · Current neurology and neuroscience reports, 2025

Abstract

PURPOSE OF REVIEW: Antithrombotic-associated intracerebral hemorrhage (ICH) is associated with high rates of morbidity and mortality. Rapid and effective antithrombotic reversal is critical for mitigating risk of hemorrhage expansion and neurological deterioration. This review provides an overview of the most recent advances in emergency antithrombotic reversal in ICH. RECENT FINDINGS: Rapid coagulopathy reversal within the first 60-90 min of hospital presentation may limit massive ICH expansion and improve outcomes. Current data suggests reversal of vitamin K antagonists with intravenous vitamin K and 4-factor prothrombin complex concentrates (4f-PCC), reversal of dabigatran with idarucizumab, and reversal or direct oral factor Xa inhibitors with either 4f-PCC or andexanet-alfa. While platelet transfusion is not suggested for antiplatelet-associated ICH, DDAVP may be reasonable, and a new reversal agent is under development for ticagrelor. Rapid reversal of antithrombotic-associated coagulopathy in the context of ICH may prevent ICH expansion and improve neurological outcomes.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansCerebral HemorrhageFibrinolytic AgentsBlood Coagulation Factors

Zusammenfassung

Antithrombotic-associated intracerebral hemorrhage (ICH) is associated with high rates of morbidity and mortality.

Warum dies für die Hirudotherapie relevant ist

This review provides an overview of recent advances in emergency antithrombotic reversal for intracerebral hemorrhage, highlighting the importance of rapid coagulopathy reversal within the first 60–90 minutes of presentation and discussing agents such as 4-factor prothrombin complex concentrate, intravenous vitamin K, idarucizumab, andexanet alfa, and DDAVP. The abstract makes no mention of leeches, hirudotherapy, hirudin, or the leech secretome, and the article addresses antithrombotic reversal entirely within conventional pharmacological contexts. Its relevance to the American Society of Hirudotherapy is therefore negligible, as it provides no information pertinent to leech-based therapies or leech-derived anticoagulants.

Zitation

Emergency Reversal of Antithrombotics in Intracerebral Hemorrhage: An Update

Li M et al. · Current neurology and neuroscience reports, 2025

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.